Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Glaukos (GKOS) Gains from Sales and Divestitures (2018 - 2025)

Glaukos (GKOS) reported Gains from Sales and Divestitures of $570000.0 for Q4 2025, up 882.76% year-over-year from $58000.0 in Q4 2024, and up 882.76% on a QoQ basis from $58000.0 in Q4 2024.

Glaukos (GKOS) has 8 years of Gains from Sales and Divestitures data on file, last reported at $570000.0 in Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 882.76% year-over-year to $570000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $570000.0 (up 882.76% YoY) and the FY2025 annual result came in at $570000.0, up 882.76% from the prior year.
  • Gains from Sales and Divestitures advanced to $570000.0 in Q4 2025 per GKOS's latest filing, from $58000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $570000.0 in Q4 2025 and bottomed at $10000.0 in Q4 2021.
  • The 5-year median for Gains from Sales and Divestitures is $63000.0 (2023), against an average of $212600.0.
  • The widest annual swing landed in 2021, when Gains from Sales and Divestitures plunged 96.77%; it then surged 3520.0% in 2022.
  • Tracing GKOS's Gains from Sales and Divestitures over 5 years: stood at $10000.0 in 2021, then surged by 3520.0% to $362000.0 in 2022, then sank by 82.6% to $63000.0 in 2023, then retreated by 7.94% to $58000.0 in 2024, then jumped by 882.76% to $570000.0 in 2025.
  • Per Business Quant, the three latest GKOS Gains from Sales and Divestitures figures stand at $570000.0 (Q4 2025), $58000.0 (Q4 2024), and $63000.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Glaukos 6.00 Bn 5.90 Bn 117.23 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 570,000.00
Dec 31, 2025 570,000.00
Dec 31, 2024 58,000.00
Dec 31, 2024 58,000.00
Dec 31, 2023 63,000.00
Dec 31, 2023 63,000.00
Dec 31, 2022 362,000.00
Dec 31, 2022 362,000.00
Dec 31, 2021 10,000.00
Dec 31, 2021 10,000.00
Dec 31, 2020 310,000.00
Dec 31, 2020 310,000.00
Dec 31, 2019 237,000.00
Dec 31, 2019 237,000.00
Sep 30, 2019 210,000.00
Sep 30, 2019 210,000.00
Jun 30, 2019 177,000.00
Jun 30, 2019 177,000.00
Mar 31, 2019 10,000.00
Mar 31, 2019 10,000.00
Dec 31, 2018 41,000.00
Dec 31, 2018 41,000.00
Sep 30, 2018 28,000.00
Sep 30, 2018 28,000.00
Jun 30, 2018 26,000.00
Jun 30, 2018 26,000.00